https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-10 BiopharmaWatch en 2026-08-10T07:15:32.710Z Biotech Catalysts to Watch: Key Developments for August 2026 https://www.biopharmawatch.com/news/OCS/oculis-acquires-privosegtor-from-accure-therapeutics BiopharmaWatch en 2026-08-10T07:01:00.000Z Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company https://www.biopharmawatch.com/news/CDRE/seegene-global-screening-approach-gmcs BiopharmaWatch en 2026-08-10T07:00:00.000Z Seegene propose une approche globale de dépistage des infections de l'appareil génital dans le cadre de la Global Million Clinical Study (GMCS) https://www.biopharmawatch.com/news/IPHA/sobi-innate-partnership-lacutamab-t-cell-lymphoma BiopharmaWatch en 2026-08-10T06:32:00.000Z Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma https://www.biopharmawatch.com/news/IPHA/innate-pharma-lacutamab-phase-3-partnership-sobi BiopharmaWatch en 2026-08-10T06:30:00.000Z Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer https://www.biopharmawatch.com/news/IPHA/innate-pharma-partnership-sobi-lacutamab-ctcl BiopharmaWatch en 2026-08-10T06:00:00.000Z Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma https://www.biopharmawatch.com/news/CMMB/online-gambling-digital-payments-bonuses BiopharmaWatch en 2026-08-10T02:24:30.000Z Ovocný Zen 1Win – CZ Start Winning https://www.biopharmawatch.com/news/CMMB/online-casinos-technology-security-promotions BiopharmaWatch en 2026-08-10T02:24:28.000Z Bezplatné Online Kasino Bez Vkladu F1 . národní území Get Bonus Now https://www.biopharmawatch.com/news/CMMB/online-gambling-casino-platform-analysis BiopharmaWatch en 2026-08-09T22:40:01.000Z Slammer Și Bandit Cu O Singură Mână Înapoi Betmen Bet — RO Unlock Offer https://www.biopharmawatch.com/news/SLN/silence-therapeutics-sanreco-trial-results BiopharmaWatch en 2026-08-09T21:00:00.000Z Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera https://www.biopharmawatch.com/news/RDNT/radnet-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-09T20:00:00.000Z RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges https://www.biopharmawatch.com/news/IRTC/kuehn-law-investigates-irhythm-technologies BiopharmaWatch en 2026-08-08T19:35:00.000Z Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm